MedPath

Nanjing Medical University First Hospital

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

176

Active:10
Completed:43

Trial Phases

6 Phases

Early Phase 1:7
Phase 1:2
Phase 2:5
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (132 trials with phase data)• Click on a phase to view related trials

Not Applicable
91 (68.9%)
Phase 4
21 (15.9%)
Early Phase 1
7 (5.3%)
Phase 3
6 (4.5%)
Phase 2
5 (3.8%)
Phase 1
2 (1.5%)

Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma

Recruiting
Conditions
Neuroblastoma (NB)
First Posted Date
2025-07-15
Last Posted Date
2025-07-15
Lead Sponsor
Nanjing First Hospital, Nanjing Medical University
Target Recruit Count
150
Registration Number
NCT07064746
Locations
🇨🇳

Nanjing First Hospital, Nanjing, Jiangsu, China

The Effect of Bupivacaine Liposome Preemptive Analgesia on Postoperative Pain and Delirium in Elderly Patients Undergoing Hip Fracture Surgery

Not Applicable
Not yet recruiting
Conditions
Postoperative Delirium
Interventions
Drug: bupivacaine liposome (ultrasound-guided high iliofascial space block)
First Posted Date
2025-07-15
Last Posted Date
2025-07-15
Lead Sponsor
Nanjing First Hospital, Nanjing Medical University
Target Recruit Count
40
Registration Number
NCT07066111
Locations
🇨🇳

Nanjing First Hospital, Nanjing, Jiangsu, China

Biomarkers of Clopidogrel Resistance for Predicting Ischemic Recurrence After Cerebral Artery Stenting

Not yet recruiting
Conditions
Ischemic Stroke
First Posted Date
2025-06-19
Last Posted Date
2025-06-19
Lead Sponsor
Nanjing First Hospital, Nanjing Medical University
Target Recruit Count
839
Registration Number
NCT07028775
Locations
🇨🇳

Nanjing First Hospital, Nanjing, Jiangsu, China

Ambrisentan for Early Low-Risk Pulmonary Arterial Hypertension

Not Applicable
Not yet recruiting
Conditions
Pulmonary Arterial Hypertension (PAH)
Interventions
Drug: Placebo
First Posted Date
2025-05-23
Last Posted Date
2025-05-23
Lead Sponsor
Nanjing First Hospital, Nanjing Medical University
Target Recruit Count
410
Registration Number
NCT06987097

Nasopharyngeal Airway Combined With Nasal High-flow Oxygen Therapy During Painless Gastroscopy in Obesity Patients

Not Applicable
Not yet recruiting
Conditions
Hypoxia
Obesity
Gastrostomy
First Posted Date
2025-05-13
Last Posted Date
2025-05-13
Lead Sponsor
Nanjing First Hospital, Nanjing Medical University
Target Recruit Count
364
Registration Number
NCT06966934
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 36
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.